Sulcid

Quick links to important sections

Sulcid

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulcid

Property Description
Active ingredient Ampicillin, Sulbactam
Form Dry powder for reconstitution (injectable solution)
Pharmacological class Penicillins/β-Lactamase Inhibitor combination
Common use Overcoming bacterial antibiotic resistance
Origin Semisynthetic

What Type of Medicine is Sulcid (Ampicillin/Sulbactam)?

Sulcid is a brand name for a prescription-only β-Lactam antibacterial belonging to the Penicillins/β-Lactamase Inhibitor combination pharmacological class. The medication is classified as a fixed-dose combination of two substances and is supplied as a sterile dry powder for reconstitution into an injectable solution for parenteral administration. This form is clinically recognized for use in hospital settings where rapid, systemic delivery is required.

The core antibiotic component, Ampicillin, is a semisynthetic compound derived from the penicillin nucleus. The combination possesses a dual-action profile. Sulcid shares its fundamental composition with other formulations, such as the widely known brand Unasyn, containing the same Ampicillin and Sulbactam active ingredients.

Composition: Why is Sulcid a Fixed Combination Product?

The preparation's strength relies on the synergy between its two active ingredients, Ampicillin Sodium and Sulbactam Sodium. The core antibiotic, Ampicillin, is fundamentally bactericidal, working by directly destroying the bacteria's cell wall.

The inclusion of Sulbactam is a protective measure; it acts as a β-Lactamase inhibitor, effectively neutralizing the bacterial enzymes (β-lactamases) that would otherwise deactivate the Ampicillin. This strategic combination is recognized as a standard approach to counteracting bacterial defense systems, ensuring the antibiotic remains protected within the body and able to perform its core function against resilient pathogens.

General Purpose of the Ampicillin/Sulbactam Combination

The general purpose of this combination product is to reliably overcome antibiotic resistance and ensure the effective clearance of infections, such as those that might complicate hospital recovery. By extending the utility of the Ampicillin component, the combination successfully widens the antibacterial coverage beyond what the antibiotic could achieve if used alone. This dual-action strategy maximizes the therapeutic potential against resilient infectious organisms.

Regulatory References

  1. NIH: Ampicillin/Sulbactam Pharmacology
  2. NIH: Sulbactam Pharmacology

What side effects are possible with Sulcid?

Possible side effects and safety information

Official regulatory documents classify the potential adverse effects of Ampicillin/Sulbactam (Sulcid) based on their observed frequency and the body system affected. These classifications establish a risk profile grounded in clinical and post-marketing data.


Frequency and System-Organ Classification

Adverse reactions are formally grouped according to their incidence rate in clinical studies:

  • Common (occurring in ge 1% of patients): Diarrhea, pain at the injection site, rash, and elevated liver enzymes (ALT/AST).
  • Uncommon (occurring in 0.1% to <1% of patients): Nausea, vomiting, headache, fatigue, phlebitis, and pruritus.

The adverse effects are primarily categorized under Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders.


Serious Adverse Reactions and Safety Constraints

The official label highlights several rare but clinically significant adverse reactions. These include life-threatening anaphylactic reactions (severe allergic responses) and severe skin reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The possibility of Clostridioides difficile-associated diarrhea (CDAD) is also documented; its onset can be delayed for up to two months following the end of treatment.

Safety constraints include a contraindication for individuals with a history of a severe allergic reaction to any penicillin. Furthermore, the official prescribing information notes that dose adjustment is necessary for patients with renal impairment. Prolonged use is associated with a specific risk of superinfection due to the overgrowth of non-susceptible organisms.

Overdose and Emergency Response

The official regulatory profile for an overdose of Ampicillin/Sulbactam defines potential severe manifestations and the required emergency response. Overexposure may lead to acute neurological adverse reactions, specifically documented as convulsions and seizures. These critical clinical signs are associated with the accumulation of high beta-lactam concentrations in the cerebrospinal fluid. The risk of such manifestations is noted to be increased in patients with impaired renal function due to the subsequent reduction in the clearance kinetics of both active ingredients.

In all suspected cases of overdose, official guidance mandates that emergency medical attention must be sought immediately. Immediate contact with emergency services is required if the affected individual exhibits severe symptoms such as collapse, trouble breathing, or cannot be awakened. Management procedures are symptomatic and supportive, as no specific antidote is documented in the official labeling. Hemodialysis is the recognized intervention documented in regulatory documents for the removal of both Ampicillin and Sulbactam from the systemic circulation.

Therapeutic Uses of Sulcid

What Sulcid treats: main uses and benefits

Ampicillin/Sulbactam is commonly used to help with conditions presenting with systemic or localized discomfort in contexts involving bacterial resistance. Its indications primarily focus on conditions characterized by acute or disruptive episodes caused by susceptible bacteria, providing relevant support during challenging clinical presentations.

It is applied across domains where additional symptomatic support is needed, specifically for infections of the skin and skin structure, the intra-abdominal cavity, and the female pelvic organs. This medication helps address symptom clusters that may become intense or disruptive by promoting the management of the acute illness.

It is relevant when supportive symptom management is appropriate, especially when dealing with organisms that are resistant to standard antibiotics. This approach supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable. It is used when symptoms cluster into patterns of symptoms related to systemic imbalance and fever, or when localized infections show symptoms related to inflammatory or irritative states.


Quick Fact: Support in Acute Symptomatic Episodes

This combination is often used during phases when symptoms become more noticeable, such as in post-operative scenarios or following trauma, where its application across domains helps address symptom clusters that create noticeable physiological strain.

Eligibility and Restrictions for Use

The eligibility for Sulcid (Ampicillin/Sulbactam) is strictly defined by official regulatory bodies based on medical history, age, and specific physiological conditions.

Contraindicated Populations

Sulcid is absolutely prohibited for use in individuals with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to ampicillin, sulbactam, or to any other beta-lactam antibacterial drugs, including penicillins and cephalosporins. It is also contraindicated in patients with a prior history of cholestatic jaundice or hepatic dysfunction specifically associated with the use of this drug combination.

Restricted Use and Exclusions

The medicine is not recommended for patients with Infectious Mononucleosis or suspected Viral Infections.

  • Organ Function: Patients with Impaired Renal Function require conditional use and adjustments to the administration frequency, as the drug's elimination is affected.
  • Pregnancy and Lactation: Use during Pregnancy is only permitted if clearly needed, as safety in human pregnancy has not been established. Caution is advised during Lactation due to the components being excreted into breast milk.

Age Eligibility

Use is established for Adults and Pediatric patients ge 1 year of age for approved indications. Caution must be exercised when administering to neonates younger than one week and premature infants due to their underdeveloped urinary system. Safety and efficacy are not established for all indications in children under one year of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ampicillin/Sulbactam's official interaction profile is structured around several pharmacokinetic and non-pharmacokinetic considerations documented in regulatory labeling. The profile does not list any medicines as formally contraindicated.

Interactions Affecting Drug Exposure

Co-administration with Probenecid is documented to increase and prolong the plasma concentrations of both the Ampicillin and Sulbactam components. This occurs because Probenecid inhibits the renal tubular secretion pathway responsible for eliminating these antibiotics. Conversely, the Ampicillin component may theoretically reduce the effectiveness of oral estrogen-containing contraceptives by interfering with the enterohepatic circulation of estrogen.

Interactions Affecting Risk and Activity

The use of Ampicillin/Sulbactam with the gout medication Allopurinol is associated with an officially recognized increased incidence of rash (skin hypersensitivity). Furthermore, the potential for pharmacodynamic antagonism is noted when the product is co-administered with bacteriostatic antibiotics, such as macrolides or tetracyclines, which may oppose the bactericidal action of Ampicillin.

Population and Product-Specific Notes

The elimination kinetics of this medicine are significantly affected by impaired renal function, which results in higher and more prolonged serum concentrations of both drugs. No known interactions with food, alcohol, or herbal products are officially specified for the parenteral (injectable) formulation, and no mandatory timing separation rules are documented for its administration.

Mechanism of Action

The action of Sulcid (Ampicillin/Sulbactam) is a combined pharmacological strategy built on two distinct but interdependent molecular mechanisms, contributing to the bactericidal effect against susceptible pathogens.

1. Direct Inhibition of Bacterial Cell Wall Construction

The Ampicillin component functions as an irreversible inhibitor by targeting and deactivating essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs). These PBPs are critical for the final cross-linking steps of the peptidoglycan layer, the main component of the bacterial cell wall. By preventing this structural assembly, the mechanism compromises the bacteria's defense against its internal osmotic pressure, triggering a cascading event resulting in the irreversible rupture and death of the cell.

2. Neutralizing Bacterial Resistance Mechanisms

The Sulbactam component acts as a dedicated protective agent, targeting and neutralizing bacterial defense enzymes called β-lactamases. These enzymes would otherwise destroy the Ampicillin molecule before it reaches its PBP target. Sulbactam traps these enzymes in a permanent complex, restoring Ampicillin's ability to engage its PBP target. This synergistic mechanism ensures that the lethal, cell-wall-destroying action of Ampicillin is applied against strains expressing susceptible beta-lactamases.

Dosage and Administration Information

How Sulcid is Used: Official Administration Guidelines

The usage of Ampicillin/Sulbactam (e.g., brand Sulcid) is defined as a parenteral, scheduled treatment that requires professional administration. The drug is a fixed-dose combination, and its dosage is calculated based on the 2:1 ratio of ampicillin to sulbactam.


Administration Scope

Field Detail
Route of administration Intravenous (IV) injection/infusion or Intramuscular (IM) injection.
Standard Dosing The typical adult dose is 1.5 g to 3.0 g (combined total) per administration. The total daily dose of the sulbactam component must not exceed 4 g.
Frequency Pattern Scheduled and divided use, typically administered every six (6) hours (q6h) or every eight (8) hours (q8h).
Course Duration Therapy is usually maintained for 5 to 14 days, continuing for 48 to 72 hours after resolution of fever or systemic signs.

Procedural and Adjustment Requirements

  • Preparation: The sterile dry powder requires reconstitution with a specified sterile diluent (e.g., sterile water or sodium chloride solution).
  • IV Administration Rate: The solution must be delivered slowly, either via IV infusion over 15 to 30 minutes or by slow injection over at least 10 to 15 minutes.
  • Renal Function Adjustment: For patients with reduced kidney function (creatinine clearance below 30 mL/min), the dosing interval must be extended (e.g., to 12 or 24 hours) to prevent accumulation of the medicine.
  • Pediatric Dosing: For children 1 year and older, the dosage is calculated based on body weight (300 mg/kg total per day) and administered in divided doses every six hours.

Connection to the overall use protocol

These official instructions establish a precise use protocol requiring professional reconstitution and controlled delivery rates in a supervised setting. This regimen is standardized by frequency adjustments based on renal function and body weight for specific populations, defining the official guidelines for administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sulcid (Ampicillin/Sulbactam)


Evidence for Use in Intra-abdominal Infections

The research examining Ampicillin/Sulbactam for intra-abdominal infections primarily consists of Randomized Controlled Trials (RCTs) and comparative studies involving hospitalized adults. These trials evaluated the combination against other established antimicrobial regimens, focusing on the clinical success rate and microbiological changes (the change in the presence of specific pathogens). Studies reported patterns in which the combination achieved measured clinical and microbiological endpoints that fell within a similar range as the comparator agents.

The evidence includes trials that examined its application in specific patient groups, such as pregnant women with acute chorioamnionitis, where the study tracked outcomes like the pattern of fever resolution. Long-term patient outcomes, particularly recurrence rates beyond the initial recovery period, are not broadly characterized across the consolidated research base, as most antibiotic trials focus on the acute treatment phase.

Evidence for Use in Skin and Skin Structure Infections

Research was evaluated in complicated skin and skin structure infections through RCTs and systematic reviews, focusing on hospitalized adults receiving intravenous therapy. The key measurements were the clinical success rates, patterns of change in localized inflammation and systemic symptoms, and microbiological changes of susceptible organisms. Findings often described the combination achieving measured clinical and microbiological endpoints that fell within a similar range as the active control agents used in the studies.

Research for Multidrug-Resistant Organisms

The research structure for the use against specific multidrug-resistant organisms, particularly Acinetobacter baumannii, is distinct. The evidence relies heavily on systematic reviews and observational cohort studies, rather than large-scale RCTs, which is a key limitation. These studies focused on critically ill patients, monitoring highly critical outcomes, including clinical response rate and patterns related to survival. Findings across the pooled data were mixed and heterogeneous due to the varying patient acuity and resistance mechanisms present in each study.

Key Studies & References

  1. A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections (NCT00952796)
  2. Comparison of ampicillin/sulbactam versus ampicillin/gentamicin for treatment of intrapartum chorioamnionitis: a randomized controlled trial

Frequently Asked Questions (FAQ)

Common questions about Sulcid (FAQ)

Q: Is Sulcid the same type of medication as [similar drug name]?

A: Sulcid is officially classified as a beta-Lactam antibacterial that belongs to the Penicillins/beta-Lactamase Inhibitor combination class. This pharmacological class is defined by its structure and its dual function. Other medicines that share this same classification or mechanism of action would be considered similar types of medication.


Q: Can Sulcid be taken by older adults?

A: Official information indicates that this medication is used in the adult population. However, regulatory documents also note that no specific data is available regarding the relationship of age to the effects of Ampicillin/Sulbactam in geriatric (older) patients.


Q: What should I know about taking Sulcid with common pain relievers?

A: Official drug interaction information has not specifically cited an interaction between Ampicillin/Sulbactam and Acetaminophen (Paracetamol), a common pain reliever. However, the label does include a general warning about potential opposition, or antagonism, when used with bacteriostatic antibiotics such as tetracyclines.


Q: Why is Sulcid sometimes used alongside other treatments?

A: The core strategy of Sulcid’s composition is to overcome common bacterial resistance mechanisms. By combining an antibiotic (Ampicillin) with a protective agent (Sulbactam), its use effectively extends the antibacterial coverage. This dual action supports its inclusion in various therapeutic strategies.


Q: Are there any known long-term research themes associated with Sulcid?

A: The consolidated research base for this product primarily focuses on acute clinical and microbiological outcomes, such as fever resolution during hospitalization. Regulatory summaries note that long-term patient outcomes beyond the initial recovery period are not broadly characterized across the published research.


Q: Is Sulcid known to cause weight changes?

A: Official adverse event reporting has documented 'unusual weight loss' among the possible side effects. It is important to note that the incidence rate of this specific effect has been categorized as unknown.


Q: Is there any research on Sulcid use in women who are planning pregnancy?

A: Official prescribing information addresses use during pregnancy, indicating it is permitted only if clearly needed. This is because safety in human pregnancy has not been definitively established in controlled studies. This regulatory caution aligns with the general consideration of reproductive planning.


Q: What happens if I miss a dose of Sulcid (general information, not instruction)?

A: Patient guidance information states that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the guidance suggests taking only that next dose. This guidance advises against taking double or extra doses.


Q: Can Sulcid affect my ability to drive or operate machinery?

A: Official regulatory summaries state that, due to the potential for certain side effects that may decrease a patient's reactivity, individuals should avoid driving or operating machinery if they feel affected by the medication.


Q: What distinguishes Sulcid from other medicines in the same category?

A: Sulcid is distinguished by its specific composition as a fixed-dose combination. It contains the antibiotic Ampicillin and the beta-Lactamase inhibitor Sulbactam, which work together to create a synergistic effect. This combination strategy is key to its utility in overcoming bacterial resistance.


Q: Do food or dairy products affect how Sulcid works?

A: Official information for the injectable (parenteral) formulation of Sulcid notes no known interactions with food. However, it is noted that the absorption of the oral form of the ampicillin component (the antibiotic part) can be reduced when taken with food.


Q: What is the shelf life or typical storage recommendation for Sulcid packaging (non-directive)?

A: The unopened vial of dry powder should be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The specific expiration date for the product is located on the outer packaging.


Q: Can people with kidney conditions use Sulcid?

A: Official guidance indicates that use in patients with impaired renal (kidney) function is permitted. However, dosing frequency requires adjustment or extension, as noted by regulatory documents, to prevent the accumulation of the medicine in the body.


Q: Are there common misunderstandings about what Sulcid is meant to do?

A: A common point of clarification is that Sulcid is not a single antibiotic. It is a combination of an antibiotic and a protective agent (Sulbactam) intended to reliably overcome antibiotic resistance. This dual-action strategy is crucial to its purpose.


Q: What information is available about Sulcid and its use in teenagers?

A: Regulatory documents define the usage for pediatric patients ge 1 year of age. The dosing for this age range, which includes teenagers, is often calculated based on body weight, ensuring appropriate levels of medication are administered.


Q: Is Sulcid available in different strengths (informational)?

A: Yes, the sterile dry powder for reconstitution is supplied in different fixed-dose strengths, such as 1.5 g, 3 g, and 15 g. All available strengths maintain the established 2:1 ratio of ampicillin to sulbactam.


Q: How often do people generally need to take Sulcid?

A: Official guidelines establish that the medication is administered on a scheduled basis. The typical frequency is every six (6) hours (q6h) or every eight (8) hours (q8h), as this consistency is part of the established treatment protocol.


Q: Are there common reasons why a doctor might switch a patient from another drug to Sulcid?

A: The strategic purpose of Sulcid is to overcome bacterial resistance. Therefore, a change in therapeutic strategy is often considered when resistance to a prior antibiotic is suspected or confirmed in the patient.


Q: Does Sulcid interact with common medications for high blood pressure?

A: Official guidance notes that the product contains a significant amount of sodium. This sodium load is a factor noted for consideration by a healthcare professional in patients with hypertension (high blood pressure) or other conditions that require sodium restriction.


Q: How long does Sulcid stay in the body after the last use (general information)?

A: Official pharmacokinetic data indicates that in individuals with normal kidney function, the body quickly eliminates the medication. Approximately 75% to 85% of both active components are excreted unchanged in the urine within the first 8 hours after administration.


Q: Are there common side effects that usually improve after a few weeks on Sulcid?

A: Official information notes that some side effects may occur as the body adjusts to the medicine. These effects may be temporary and may resolve or go away during the course of treatment.


Q: Can Sulcid be taken with antacids?

A: Official interaction profiles for the parenteral (injectable) formulation do not specify an interaction with antacids. This is because this route of administration bypasses the digestive system where antacids primarily function.


Q: What is the non-directive guidance for what to do if a dose is missed?

A: Patient guidance information states that if a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the guidance suggests taking only that next dose, and advises avoiding double or extra doses.


Q: Does the time of day matter when taking Sulcid?

A: Official administration schedules emphasize the importance of maintaining a scheduled, fixed interval (e.g., every six or eight hours) for the dose. This interval consistency is the focus of the regulatory protocol, rather than administration at a specific time of day.


Q: Is the purpose of Sulcid to treat symptoms or the underlying cause?

A: Sulcid is classified as a bactericidal drug. Its mechanism of action involves inhibiting the cell wall construction of susceptible bacteria, which means its purpose is to address the underlying cause of the bacterial infection.

How should Sulcid be stored and disposed of?

The official requirements for storing and disposing of Sulcid (Ampicillin/Sulbactam) focus on maintaining the integrity of the dry powder and the stability of the reconstituted solution.

Item Official Regulatory Statement
Dry Powder Storage Store the unopened vial at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), not exceeding 30 C (86 F).
Solution Stability Reconstitution must occur under aseptic conditions. The final solution has a highly time-dependent stability (e.g., 1 to 8 hours at room temperature, longer under refrigeration) based on the diluent used.
Child Safety Keep all medicines out of reach of children.
Disposal The product is for single use only. Any unused portion or waste material must be discarded in accordance with local requirements to avoid environmental release.

These constraints define how the sterile powder must be protected from heat and detail the critical stability limits for the injectable solution, ensuring adherence to established pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulcid found in:

A-Z Index: